pharmaceutical sales: 100% (2025)

top 3 markets:

1. japan: approx. 60%
2. usa: approx. 25%
3. europe: approx. 10%

ono pharmaceutical co., ltd. generates its sales entirely from the pharmaceutical industry, with a focus on the development and marketing of medications. the domestic market of japan is the largest revenue contributor, followed by the usa, which plays a significant role through strategic partnerships and licensing agreements. europe, although smaller compared to the other markets, remains an important area of growth for the company. the focus on innovative therapies and expansion into international markets are central components of ono pharmaceutical's growth strategy.

production sites:

• japan (main production country)
• additional production facilities in asia and europe

ono pharmaceutical co., ltd. has its main production facilities in japan, where it manufactures the majority of its pharmaceutical products. the company also operates additional production facilities in other asian countries as well as in europe to strengthen its global supply chain and efficiently serve demand in various markets.

this geographical distribution of production sites enables ono pharmaceutical to optimize production costs and shorten delivery times for international markets.

revenue growth: 7.8% (estimated for 2024)
research & development investments: 20% of revenue (estimated for 2024)

ono pharmaceutical co., ltd. pursues a growth strategy that is heavily focused on research and development (r&d). the company invests a significant portion of its revenue in the development of new drugs, particularly in the fields of oncology and immunology. these investments are intended to strengthen the company's pipeline and secure future sources of revenue.

in addition, ono relies on strategic partnerships and alliances with other pharmaceutical companies to expand access to new technologies and markets. these collaborations enable the company to diversify its product range and increase its global presence.

another key focus of the growth strategy is the expansion into international markets, particularly in asia and north america. by expanding distribution networks and adapting products to local needs, ono plans to increase its market share in these regions.

imported raw materials/ingredients: pharmaceutical active ingredients, chemicals, packaging materials

main import countries: usa, germany, china, india

ono pharmaceutical co., ltd. imports a variety of raw materials and ingredients necessary for the production of their pharmaceutical products. this includes pharmaceutical active ingredients and special chemicals used in drug manufacturing.

the usa and germany are important suppliers of advanced pharmaceutical active ingredients and technologies. china and india are significant sources for generic active ingredients and cost-effective chemicals. packaging materials, crucial for the safe and efficient distribution of medications, are also sourced from various international markets.

this diversification of suppliers enables ono pharmaceutical to maintain a stable supply chain and respond flexibly to global market changes.

market share in japan: 10% (estimated 2025)
r&d expenses: 20% of revenue (2024)
patent portfolio: over 1000 active patents (2025)

ono pharmaceutical co., ltd. has a significant competitive advantage due to its strong position in the japanese pharmaceutical market, where it holds an estimated market share of 10%. this position is supported by substantial investments in research and development, which account for about 20% of revenue. this enables the company to continuously develop and bring innovative products to the market.

the extensive patent portfolio with over 1000 active patents secures ono pharmaceutical a technological edge and protects its products from imitators. additionally, the company has strategic partnerships and alliances with other global pharmaceutical companies that further enhance its research and development capabilities.

overall, ono pharmaceutical's competitive advantage is strong, particularly through its innovation capabilities and market presence in japan. continuous investment in r&d and the protection of intellectual property are crucial factors that differentiate the company in a competitive industry.

institutional investor share: approximately 60% (estimated for 2025)
insider buys/sells: no significant transactions in the last year (estimated for 2025)

the institutional investor share in ono pharmaceutical co., ltd. typically stands at around 60%. this figure is based on historical data and typical industry comparisons for large pharmaceutical companies in japan. institutional investors include pension funds, investment funds, and other major financial institutions that often invest in stable and established companies.

in 2025, there were no significant insider buys or sells publicly disclosed. this suggests that management and other insiders may have confidence in the current company strategy and valuation. such transactions are often seen as indicators of the company's future performance.

market share of ono pharmaceutical co., ltd.: estimated 5-7% (2025)

major competitors and their market share:

1. takeda pharmaceutical co. ltd.: 10-12%
2. astellas pharma inc.: 8-10%
3. daiichi sankyo co., ltd.: 7-9%
4. eisai co., ltd.: 6-8%
5. chugai pharmaceutical co., ltd.: 5-7%

moat of ono pharmaceutical: ono pharmaceutical has a moderate moat, primarily characterized by its strong research and development as well as strategic partnerships, especially in the field of immuno-oncology. an example of this is the collaboration with bristol-myers squibb in the development of immunotherapies.

compared to its competitors, ono pharmaceutical has a specialized focus that gives them advantages in certain niche markets. however, larger companies like takeda and astellas have a broader product mix and a stronger global presence, providing them with a more comprehensive moat.

overall, ono pharmaceutical has a significant advantage in specific therapeutic areas, but larger competitors could have a stronger general moat due to their resources and global reach.

revenue growth: 4.8% (2024) research and development expenses: 15% of revenue (2024) market share in oncology: 8% (2024)

ono pharmaceutical co., ltd. recorded a revenue growth of 4.8% in 2024, indicating stable demand for its pharmaceutical products, especially in oncology. the company continues to invest heavily in research and development, with expenses accounting for 15% of revenue. this demonstrates a clear commitment to innovation and the development of new therapies.

the 8% market share in oncology highlights ono pharmaceutical's strong position in an important and growing sector of the healthcare industry. these factors suggest that the company is well positioned to benefit from future growth opportunities.

overall, ono pharmaceutical could be an attractive investment for investors interested in long-term growth in the healthcare sector, particularly due to its ongoing investments in research and development and strong market position in oncology.

dividend yield: 3.2% (2025, estimated)
dividend history: continuous payout over the last 5 years

ono pharmaceutical co., ltd. has regularly distributed dividends to its shareholders in recent years. the dividend yield for the year 2025 is estimated to be around 3.2%, which can be considered solid compared to other companies in the industry.

the reliability of dividend payments is supported by the company's stable financial performance. ono pharmaceutical has a strong balance sheet and consistently generates positive cash flows, which underpins its ability to pay dividends. historically, the company has maintained its dividend policy, indicating a long-term commitment to payout to shareholders.